This study was designed to explore the association between elevated platelet to lymphocyte ratio (PLR) and prognosis of patients with non-small cell lung cancer (NSCLC) by meta-analysis. A total of 11 studies with 3,430 subjects were included and the combined hazard ratio (HR) and 95% confidence intervals (95% CI) were calculated. The data showed that elevated PLR predicted poor overall survival (OS) (HR = Lung cancer is one of the most commonly diagnosed cancer forms and the leading cause of cancer related mortality in both developed and developing countries 1 . Lung cancer mainly consists of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC accounts for more than 80% of all lung cancer cases. The major treatment methods for NSCLC are surgery, chemotherapy and radiotherapy, in addition, targeted therapies on the specific gene mutations (e.g. EGFR, ALK etc.) have shown encouraging effects 2, 3 . In spite of these, the 5-year survival rate of NSCLC is only 16.6% because about two-thirds of NSCLC patients are at locally advanced or metastatic stage when diagnosed 4, 5 . The poor survival of NSCLC is partly due to absence of efficacious biomarkers. Traditional prognostic biomarkers such as ECOG PS, weight loss and pleural effusion provided limited implication for treatment and several emerging biomarkers including EGFR mutations and ALK gene rearrangements only provided useful information for clinical management for a small proportion of patients 6, 7 . The identification of novel prognostic factors could help stratify risk patients and guide therapy modalities selection.
Lung cancer is one of the most commonly diagnosed cancer forms and the leading cause of cancer related mortality in both developed and developing countries 1 . Lung cancer mainly consists of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC accounts for more than 80% of all lung cancer cases. The major treatment methods for NSCLC are surgery, chemotherapy and radiotherapy, in addition, targeted therapies on the specific gene mutations (e.g. EGFR, ALK etc.) have shown encouraging effects 2, 3 . In spite of these, the 5-year survival rate of NSCLC is only 16 .6% because about two-thirds of NSCLC patients are at locally advanced or metastatic stage when diagnosed 4, 5 . The poor survival of NSCLC is partly due to absence of efficacious biomarkers. Traditional prognostic biomarkers such as ECOG PS, weight loss and pleural effusion provided limited implication for treatment and several emerging biomarkers including EGFR mutations and ALK gene rearrangements only provided useful information for clinical management for a small proportion of patients 6, 7 . The identification of novel prognostic factors could help stratify risk patients and guide therapy modalities selection.
Accumulated evidence show that host's inflammatory response plays an important role in cancer progression and prognosis 8, 9 . In recent years, a variety of inflammatory indices such as neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), C-reactive protein (CRP) and modified Glasgow prognostic score (mGPS) have attracted extensive attention for their prognostic efficiency in cancer patients 10, 11 . Notably, as an easily measured blood-based parameter, PLR was reported as an unfavourable prognostic factor in various solid tumors including gastric cancer 12 , breast cancer 13 , colorectal cancer 14 and NSCLC 15 . However, the data concerning the prognostic value of PLR in NSCLC were inconsistent. Liu et al. 15 reported that elevated PLR was associated with poor prognosis in patients with NSCLC receiving chemotherapy.
Cannon et al. 16 also showed that patients with high pretreatment PLR had shorter overall survival after stereotactic radiation therapy. In contrast, Pinato et al. 17 failed to find the prognostic significance of PLR in primary operable NSCLC and Wu et al. 18 also did not find correlation between PLR and prognosis of NSCLC. We thus
Results
The characteristics of included studies. The literature selection process of the eligible studies was presented in Fig. 1 . A total of 11 studies 15-25 with 3,430 patients were included in the meta-analysis. The basic characteristics of the primary studies were shown in Table 1 . Of these studies, four studies 15, 18, 20, 24 were conducted in China, two studies 16, 23 were conducted in USA, two studies 19, 22 were performed in Turkey, two studies 21, 25 were carried out in Japan and one study 17 was conducted in UK. Three studies 15, 18, 19 included patients with advanced tumor stages, seven studies 16, 17, 20, 21, [23] [24] [25] involved patients with early stages and one study 22 included patients with all tumor stages. The articles were published from 2013 to 2015 and the NOS scores of the included studies ranged from 7-9. Five studies [16] [17] [18] 21, 24 gave the definition of OS and defined OS as the length of time from treatment to day of death or last follow-up. The other six studies 15, 19, 20, 22, 23, 25 generally described OS as overall survival. One study 24 provided the definition of DFS and defined DFS as theduration of time between the date of treatment and the date of first recurrence or last follow-up. Three studies 19, 20, 25 generally described DFS as disease-free survival. One study 18 defined PFS as the time from treatment initiation until disease progression. All the 11 studies [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] investigated the prognostic value of PLR in OS and five studies [18] [19] [20] 24, 25 explored the prognostic significance of PLR in DFS/PFS. The sample sizes in the included syudies ranged from 59 to 1043. Four studies 18, 20, 21, 24 were classified as large sample size (n > 300) studies and seven studies [15] [16] [17] 19, 22, 23, 25 were small sample size (n < 300) studies. The cut-off values used by the included studies ranged from 106 to 300, the median value of which was 171, so we selected PLR = 180 to divide the cut-off values in the following subgroup analysis.
PLR and OS in NSCLC.
Eleven studies [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] with 3,430 patients reported the data of pretreatment PLR and OS in NSCLC. Elevated PLR was associated with poor OS (HR = 1.42; 95% CI: 1.25-1.61, p < 0.001) although with heterogeneity (I 2 = 63.6, P h = 0.002; Table 2 , Fig. 2 ).
PLR and DFS/PFS in NSCLC.
There were five studies [18] [19] [20] 24, 25 with 1,635 patients presenting the HR and 95% CI of PLR and DFS/PFS. The combined data showed that elevated PLR was associated with shorter DFS/ PFS (HR = 1.19; 95% CI: 1.02-1.4, p = 0.027) with moderate heterogeneity (I 2 = 46.8, P h = 0.111; Table 2 , Fig. 3 ).
Subgroup analyses.
To detect the potential source of heterogeneity, subgroup analyses stratified by ethnicity, sample size, treatment methods and PLR cut-off were performed. As shown in Table 2 , elevated PLR did not predict poor OS in patients in large sample studies (HR = 1.44; 95% CI: 0.94-2.21, p = 0.098; I 2 = 80.8, P h = 0.001), however, elevated PLR had enhanced prognostic efficiency for poor OS in Caucasians (HR = 1.59; 95% CI: 1.27-1.98, p < 0.001; I 2 = 15.2, P h = 0.318) and when the cut-off value of PLR was more than 180 (HR = 1.61; 95% CI: 1.3-1.99, p < 0.001; I 2 = 11.8, P h = 0.339). As for the PLR in DFS/PFS, the results showed that elevated PLR did not predict poor DFS/PFS in Asians (HR = 1.12; 95% CI: 0.94-1.34, p = 0.205; I 2 = 46.6 P h = 0.154) whereas high PLR was correlated with shortened DFS/PFS in small sample studies(HR = 1.55; 95% CI: 1.09-2.22, p = 0.015; I 2 = 13.8,P h = 0.281) ( Table 2 ).
Sensitivity analysis. Each single study was omitted every time to estimate the influence of individual data sets on the combined HR. The results showed that the pooled HRs for OS and DFS/PFS were not substantially changed (Fig. 4) , indicating the robustness of our findings. 
Discussion
In the present study, using the method of meta-analysis, we explored the prognostic impact of pretreatment PLR on OS and DFS/PFS in patients with NSCLC. By combining the HRs and 95% CIs from eleven primary studies 15-25 with 3,430 subjects, we showed that elevated PLR was associated with poor OS (HR = 1.42; 95% CI: 1.25-1.61, p < 0.001) and poor DFS/PFS (HR = 1.19; 95% CI: 1.02-1.4, p = 0.027) in NSCLC. Furthermore, stratified analysis showed that high PLR had consistent prognostic value in NSCLC in diverse subgroup populations expect for patients included in large sample size studies (HR = 1.44; 95% CI: 0.94-2.21, p = 0.098), whereas patients with Caucasuian ethnicitic background and PLR > 180 could better predicted poor OS. The stratified analysis also showed that high PLR had no prognostic efficiency for DFS/PFS in Asian patients. All of the studies were published since 2013, highlighting the recent interest in PLR as an attractive prognostic factor. To our knowledge, this was the first meta-analysis to investigate the association between PLR and NSCLC prognostication. Inflammation and immune responses were recognized as important stimulators for tumorigenesis since it was first proposed by Virchow 26 in the 19th century. In the past several decades, a large amount of studies investigating mechanisms by which inflammation promote tumorigenesis suggested that inflammatory cells are important cross-talk factors between chronic inflammation and neoplastic growth 27 . Lung cancer patients often have the common feature of chronic inflammation, such as COPD 27, 28 . In the tumor microenvironment, macrophages, neutrophils, platelets and lymphocytes produce inflammatory cytokines and chemokines, which could facilitate tumor progression 29 . A variety of cytokine proteins such as IL-1, IL-6 and TNF could enhance tumor cells' capability to metastasize 30 . Leukocyte infiltration was also shown to be related with tumor angiogenesis 31 . Readily available blood based parameters including NLR, PLR and mGPS could adequately reflect the cancer-related inflammatory status and are widely investigated as prognostic factors in NSCLC 32, 33 . The results of this meta-analysis provided evidence supporting elevated PLR as a prognostic factor for OS in NSCLC, which was in line with a previous meta-analysis 34 . In addition, we noticed that in the previous work 34 , a variety of solid tumors were included for analysis, except for NSCLC. The previous meta-analysis 34 searched literature until June 2013, but the first eligible primary study 15 included in our meta-analysis was published on December 2013. Therefore, the current study first provided the statistical evidence for PLR's prognostic role in NSCLC by meta-analysis. Interestingly, after subgroup analysis dichotomized by sample sizes of included studies, we found that high PLR no longer predicted poor OS in patients attending large sample size studies. (Table 2) . However, four studies 18, 20, 21, 24 with 2,487 patients were identified as large sample studies, one 21 of which recruited 1,043 subjects. This study 21 may have significant impact on the results of subgroup analysis stratified by sample size, therefore, the results should be interpreted with caution. Furthermore, subgroup analysis demonstrated that patients with Caucasian ethnicitic background and a higher PLR (>180) had augmented prognostic value, because a higher PLR represented more seriously impaired immune functions in cancer patients. The prognostic role of PLR for DFS/PFS was also detected in our study whereas elevated PLR did not suggest poor DFS/PFS in Asian patients in subgroup analysis. The ethnicitic heterogenicity may account for the results. Neutrophil-to-lymphocyte ratio (NLR) was another easily available and useful index for prognosis prediction in NSCLC. Our previous work 35 had demonstrated NLR might be a predicative factor of poor prognosis for NSCLC patients. In the current study, we intended to explore the prognostic role of PLR in NSCLC, which was usually compared with NLR in prognostication. We pooled coflicting data from 11 studies and showed the prognostic value of PLR for NSCLC, which extended the inflammatory prognostic factors for NSCLC.
The present study had several limitations. First, obvious heterogeneity existed in this meta-analysis. Although sensitivity analysis and publication bias test indicated the credibility of the results, we could not rule out that different study criteria used in the primary resulted in the discrepancies between studies. Second, the nonuniform cutoff value defining elevated PLR may not be applicable for clinical use, an identical cutoff value was needed. Finally, the summary HR and 95% CI rather than individual patient data were used for calculation of pooled HR and 95% CI in this meta-analysis.
In conclusion, our study for the first demonstrated the prognostic role of elevated PLR for poor OS and DFS/ PFS in NSCLC by meta-analysis. Considering the limitations of our study, further well-designed studies using uniform PLR cutoff value are warranted to test our results.
Methods
Search strategy and eligibility criteria. The databases of Web of Science, Embase and Pubmed were thoroughly searched until December, 2015. The following terms were used in separation or in combination: "PLR", "platelet-lymphocyte ratio", "platelet to lymphocyte ratio", "lung cancer", "lung carcinoma" or "NSCLC". Reviews and reference lists were also manually retrieved for additional publications. The publication language was limited to English.
The inclusion criteria were: 1) patients pathologically diagnosed as NSCLC; 2) PLR was measured by blood-based methods before formal treatment; 3) HRs and 95% CIs for PLR in OS and (or) DFS/PFS were reported in text or sufficient data was provided for the calculation of HRs and 95% CIs. 4) full text papers published in English.
The exclusion criteria were as follows: 1) review, meeting abstract, letter, not full text in English; 2) duplicate data; 3) nonhuman studies; 4) did not present the cut-off value for elevated PLR.
Data extraction. Two independent reviewers (XB,G and XS,G) extracted the following information from the eligible studies: the surname of the first author, year of publication, study country, sample size, treatment methods, cut-off value of high PLR and survival data. Disagreements were resolved by joint discussion.
Quality assessment. The quality assessment of primary studies was performed according to Newcastle-Ottawa quality assessment Scale (NOS)(http://www.ohri.ca/programs/clinical_epidemiology/oxford. asp). This scale is composed of three parts: selection, comparability and outcome assessment. The full mark is 9 points and studies labeled with ≥6 points were regarded as high-quality researches.
Statistical analysis. The hazard ratio (HR) with 95% confidence intervals(95% CI) were directly obtained from the articles or estimated according to the methods reported by Tierney et al. 36 . Heterogeneity among primary studies was evaluated using the Cochran Q test and I 2 statistic. Cochran Q test'p value < 0.10 or I 2 > 50% indicated large heterogeneity between studies and random effects models (DerSimonian Laird method) was used to calculate the pooled HR and 95% CI. Otherwise, the fixed effects model (Mantel-Haenszel method) was used. Studies with sample size >200 were considered as large sample studies, otherwise was regarded as small sample size. Subgroup analyses stratified by ethnicity, sample size, treatment methods and PLR cut-off were carried out.
Sensitivity analysis was conducted by omitting each single study and recalculating their HRs. Publication bias was evaluated using Begg's test 37 . All statistical analyses were performed using Stata 12(Stata Corp., College Station, Texas). P < 0.05 was considered statistically significant.
